

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A standard for measuring [“]oxidized LDL/β2-GPI complex[”] in a sample, which comprises [“]a complex having oxidized LDL bound covalently to β2-GPI[”] as an ingredient, wherein the complex has the following properties (a) and (b):
(a) oxidized LDL and β2-GPI constituting the complex are substantially not dissociated in the presence of 100 U/ml heparin, and
(b) oxidized LDL and β2-GPI constituting the complex are substantially not dissociated in the presence of 10 mM MgCl₂.
2. **(Currently amended)** A standard for measuring [“]oxidized LDL/β2-GPI complex[”] in a sample, which comprises [“]oxidized LDL/β2-GPI complex obtainable by incubating oxidized LDL and β2-GPI under the conditions of 37°C and pH 7.4 for 16 hours[”] as an ingredient, wherein the complex has the following properties (a) and (b);
(a) oxidized LDL and β2-GPI constituting the complex are substantially not dissociated in the presence of 100 U/ml heparin, and
(b) oxidized LDL and β2-GPI constituting the complex are substantially not dissociated in the presence of 10 mM MgCl₂.
3. **(Canceled)**
4. **(Presently presented)** The standard according to claim 1, wherein the sample is a sample derived from a living body.
5. **(Original)** The standard according to claim 4, wherein the sample derived from a living body is blood.
6. **(Withdrawn-currently amended)** A method of measuring [“]oxidized LDL/β2-GPI complex[”] in a sample, which comprises using the standard according to claim 1.

7. **(Withdrawn-currently amended)** The measurement method according to claim 6, which comprises at least a step of covalently binding [“]oxidized LDL[”] to [“] β 2-GPI[”] in a sample.
8. **(Withdrawn-currently amended)** The measurement method according to claim 6, which comprises at least a step of previously incubating [“]oxidized LDL[”] and [“] β 2-GPI[”] in a sample, under the condition of pH 3 to 9.
9. **(Withdrawn-currently amended)** The measurement method according to claim 6, which comprises at least a step of dissociating [“]complex having [‘]oxidized LDL[’] bound electrostatically to [‘]a protein, a polypeptide, an amino acid, an aminosugar or an aminolipid[”] in a sample.
10. **(Withdrawn-currently amended)** A method of detecting a disease, which comprises measuring [“]oxidized LDL/ β 2-GPI complex[”] in a sample by using the measurement method according to claim 6 and correlating the measured [“]complex in the sample[”] with a disease.
11. **(Withdrawn)** The detection method according to claim 10, wherein the disease is selected from the group consisting of the antiphospholipid syndrome, thrombosis, arterial thrombosis, venous thrombosis, pregnancy morbidity, renal disease, arteriosclerosis and diabetes.
12. **(Currently amended)** A kit for measuring [“]oxidized LDL/ β 2-GPI complex[”] in a sample, which comprises ~~as a constituent ingredient~~ the standard according to claim 1.
13. **(Currently amended)** The measurement kit according to claim 12, ~~which further comprises~~comprising an [“]antibody capable of recognizing [‘]oxidized LDL/ β 2-GPI

complex[“] as a constituent ingredient.

14. (Previously presented) The measurement kit according to claim 12 , which is used in detection of a disease.

15. (Currently amended) An antigen for measuring an [“]antibody capable of recognizing [‘]oxidized LDL/β2-GPI complex[”]] in a sample, which comprises a [“]complex having oxidized LDL bound covalently to β2-GPI[”]] as an ingredient.

16. (Currently amended) An antigen for measuring an [“]antibody capable of recognizing [‘]oxidized LDL/β2-GPI complex[”]] in a sample, which comprises an [“]oxidized LDL/β2-GPI complex obtainable by incubating oxidized LDL and β2-GPI under the conditions of 37°C and pH 7.4 for 16 hours[”]] as an ingredient.

17. (Currently amended) The antigen according to claim 16, wherein the [“]oxidized LDL/β2-GPI complex obtainable by incubating oxidized LDL and β2-GPI under the conditions of 37°C and pH 7.4 for 16 hours[”]] has the following properties (a) and (b):

- (a) oxidized LDL and β2-GPI constituting the complex are substantially not dissociated even in the coexistence presence of 100 U/ml heparin, and
- (b) oxidized LDL and β2-GPI constituting the complex are substantially not dissociated even in the coexistence presence of 10 mM MgCl₂.

18. (Withdrawn-currently amended) A method of measuring [“]antibody capable of recognizing [‘]oxidized LDL/β2-GPI complex[”]] in a sample, which comprises using the antigen according to claim 15.

19. (Withdrawn-currently amended) A method of detecting a disease, which comprises measuring [“]antibody capable of recognizing [‘]oxidized LDL/β2-GPI complex[”]] in a sample by using the measurement method according to claim 18 and correlating the measured

[["]]antibody in the sample[["]] with a disease.

20. (Withdrawn) The detection method according to claim 19, wherein the disease is selected from the group consisting of the antiphospholipid syndrome, thrombosis, arterial thrombosis, venous thrombosis, pregnancy morbidity, renal disease, arteriosclerosis and diabetes.

21. (Previously presented) A solid phase having the antigen according to claim 15 immobilized thereon.

22. (Currently amended) A kit for measuring an [["]]antibody capable of recognizing [["]]oxidized LDL/β2-GPI complex[["]] in a sample, which comprises the solid phase according to claim 21 ~~as a constituent ingredient~~.

23. (Currently amended) The measurement kit according to claim 22, which further comprises ~~as a constituent ingredient~~, a substance capable of binding to the [["]]antibody capable of recognizing [["]]oxidized LDL/β2-GPI complex[["]].

24. (Original) The measurement kit according to claim 23, which is used in detection of a disease.

25. (Withdrawn-currently amended) A method of measuring an immune complex in a sample, which comprises using [["]]antibody capable of recognizing β2-GPI[["]] and/or [["]]antibody capable of recognizing LDL[["]] and an anti-IgG antibody.